Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography

The effect of pyridinolcarbamate treatment in atherosclerosis obliterans was evaluated in 47 patients during a double-blind crossover trial using the mean of crest time from toe plethysmography.After the initial 3 weeks of placebo washout a 10 week regimen of placebo or pyridinolcarbamate (1.5Gm. daily) and another 10 week of alternative regimen were given successively.1) Twenty-two cases completed the trial and after the pyridinolcarbamate regimen the prolonged crest time was improved in 8 out of total 44 legs (18.2%), no change in 36 (81.8%) and worsening in none. After the placebo regimen, there was improvement in none, no change in 37 out of 44 legs (84.1%) and worsening in 7 (15.9%). This difference was statistically significant (p